2357-39-3

Usage

Oxazolone derivative

Contains both a trifluoromethyl and an isopropyl group

Use in organic synthesis and medicinal chemistry

A versatile building block for the creation of pharmaceuticals and other bioactive molecules

Unique properties

The trifluoromethyl group confers unique properties to the compound, making it useful in the development of novel drugs and materials.

Upstream product

• 516-06-3 D,L-valine 
• 407-25-0 trifluoroacetic anhydride 
• 72-18-4 L-valine 

Downstream Products

• 51111-43-4 4-isopropyl-4-p-tolylsulfanyl-2-trifluoromethyl-4H-oxazol-5-one 
• 51111-40-1 4-isopropyl-2-phenylsulfanyl-2-trifluoromethyl-2H-oxazol-5-one 
• 51111-41-2 4-isopropyl-2-p-tolylsulfanyl-2-trifluoromethyl-2H-oxazol-5-one 
• 51111-42-3 4-isopropyl-4-phenylsulfanyl-2-trifluoromethyl-4H-oxazol-5-one 
• 110582-79-1 (S)-3-Methyl-N-((S)-1-phenyl-ethyl)-2-(2,2,2-trifluoro-acetylamino)-butyramide 
• 62227-09-2 (S)-1-[3-Methyl-2-(2,2,2-trifluoro-acetylamino)-butyryl]-pyrrolidine-2-carboxylic acid methyl ester 
• 62227-12-7 (S)-2-[(R)-3-Methyl-2-(2,2,2-trifluoro-acetylamino)-butyrylamino]-3-phenyl-propionic acid methyl ester 
• 4817-67-8 N-trifluoroacetyl-L-valinyl-L-phenylalanine methyl ester 
• 87341-27-3 5-Methyl-1-phenyl-hex-1-yne-3,4-dione 
• 87341-20-6 3-(5-Hydroxy-4-isopropyl-5-phenyl-2-trifluoromethyl-2,5-dihydro-oxazol-2-yl)-propionic acid tert-butyl ester 
• 87341-21-7 3-(5-Hydroxy-4-isopropyl-5-phenylethynyl-2-trifluoromethyl-2,5-dihydro-oxazol-2-yl)-propionic acid tert-butyl ester 
• 7332-95-8 3-methyl-1-phenylbutane-1,2-dione 
• 759-05-7 3-methyl-2-ketobutanoic acid 
• 51111-46-7 2-(p-Tolylthio)-2-(trifluoracetamido)-isovaleriansaeure 

Relevant academic research and scientific papers

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Synthesis-guided structure revision of the sarcodonin, sarcoviolin, and hydnellin natural product family

A sweeping structural revision of the sarcodonin natural product family (published structures 1a-13a) is proposed after extensive studies aimed at their chemical synthesis. Key features of revised structure 1b include replacement of the N,N-dioxide moiety with an oxime, ring-opening of the central diketopiperazine, and transposition of the terphenyl wing from the 1β-2β position of 1a to the 2β-3β position of 1b. This structure revision arose from the serendipitous synthesis of a benzodioxane aminal (44) whose structure was unambiguously determined by X-ray crystallography and whose spectral properties bore considerable resemblance to the published data for the sarcodonins. A versatile new method for O-arylation of hydroxamic acids is also reported herein, as well as a manganese(III)- mediated α-oxidation of hydroxamic acids to aminals.

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.

Eine neue Aminoazirin-Reaktion. Bildung von 3,6-Dihydropyrazin-2(1H)-onen

The reaction of 3-(dimethylamino)-2H-azirines 1 and 2-(trifluoromethyl)-1,3-oxazol-5(2H)-ones 5 in MeCN or THF at 50-80 deg leads to 5-(dimethylamino)-3,6-dihydropyrazin-2(1H)-ones 6 (Scheme 3).Reaction mechanisms for the formation of 6 are discussed: eit

UMWANDLUNG VON α-AMINOSAEUREN IN α-DIKETONE UEBER OXAZOLINZWISCHENSTUFEN

A four step sequence for the conversion of α-amino acids into α-diketones under mild conditions is desribed.

Gas chromatographic and mass spectrometric characteristics of 2-trifluoromethyl-3-oxazol-5-ones. A potentially useful derivative for α-amino acids

The mass spectra of a number of 2-trifluoromethyl-3-oxazol-5-ones, prepared from protein amino acids, have been recorded. The compounds have been separated by gas chromatography using binary column techniques. Analysis of the mass spectra has identified m